Key facts
- This page summarizes Mr. Bryan Baldasare's Form 4 filing for InMed Pharmaceuticals Inc. (INM).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 23 Dec 2024, 09:18.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
The options were granted on 12/20/2024 and will vest 100% on the one-year anniversary of the grant date (December 19, 2025) or immediately prior to the next Annual General Meeting, whichever is sooner.
Footnote F2
On November 14, 2024, the common stock of InMed was reverse split on a 1-for-20 basis. This number reflects that reverse stock split.